Robert Wessman is a pharma executive with nearly 20 years’ experience in the industry, including time as CEO of Actavis Group, which became one of the largest generic pharmaceutical companies in the world for nine years.Robert Wessman is currently Executive Chairman of Alvogen, which has grown from a small US business into an international pharmaceuticals company with commercial operations in 20 countries and 1,700 employees.Since founding the business in 2009, Alvogen has made significant progress in its goal to become a leading generics player. Companies led by Wessman have achieved an impressive CAGR with Alvogen’s CAGR for the years 2009 to 2020 at 35% and Actavis’ CAGR at 55% during Wessman’s leadership from 1999 to 2007. In 2018, the company posted global revenues exceeding US$1bn, while sister company, Alvotech, is primed to take advantage of the market shift towards biosimilars.At Alvotech, Robert Wessman serves as the Chairman of the Board and founder of the business in 2013. He is the Chairman of the board of Lotus Pharmaceutical (Taiwan TWSE ticker:1795) and in July 2019, he took up a seat on the Board of Directors of Fuji Pharma in Japan, to further strengthen the partnership between the two companies in development and commercialization of biosimilars in Japan.Robert is also the founder of US based specialty pharmaceutical company Almatica and injectable pharmaceutical compant Almaject.Robert Wessman was named Best CEO in the Pharmaceuticals Industry 2018 by European CEO magazine.Specialities: emerging markets, entrepreneurship, managing rapid growth, cross-border expansion, and successful merger integration.